Last updated: September 2, 2026
Elbasvir/grazoprevir, marketed by Merck & Co. as Zepatier, generated a rapid but short-lived commercial ramp after its 2016 U.S. approval. Merck’s reported sales reached roughly $1 billion in 2017 before declining as pangenotypic direct-acting antivirals, lower-cost alternatives and reduced hepatitis C treatment volumes compressed demand. The product remains an approved oral treatment for hepatitis C virus, but its commercial position is weak relative to newer regimens such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir.
What is elbasvir/grazoprevir and how does it work?
Elbasvir/grazoprevir is a fixed-dose, once-daily combination of two direct-acting antiviral agents:
| Component |
Target |
Role |
| Elbasvir |
HCV NS5A protein |
Inhibits viral replication and assembly |
| Grazoprevir |
HCV NS3/4A protease |
Inhibits viral polyprotein processing |
Zepatier is approved for adults with chronic HCV genotype 1 or genotype 4 infection, with or without ribavirin in specified patient populations. The regimen is generally administered for 12 weeks, although treatment duration and ribavirin use depend on genotype, prior treatment history, cirrhosis and baseline resistance-associated substitutions.
The product is not a pangenotypic therapy. That limitation became commercially important as treatment guidelines shifted toward regimens covering most or all major HCV genotypes with fewer baseline testing requirements.
The U.S. Food and Drug Administration approved Zepatier on January 28, 2016. The approval made Merck a major competitor to Gilead Sciences, which had established the HCV market with Harvoni and Sovaldi. [1]
How large was the elbasvir/grazoprevir market?
Zepatier entered a high-value market but faced rapid price and volume erosion. U.S. list pricing was approximately $54,600 for a standard 12-week course at launch, before rebates, discounts and government pricing. Net prices were materially lower for Medicaid, public health programs and negotiated commercial contracts.
Merck Zepatier sales trajectory
| Fiscal year |
Reported Zepatier sales, approximate |
| 2016 |
$500 million-$550 million |
| 2017 |
$1.0 billion |
| 2018 |
$658 million |
| 2019 |
$470 million-$500 million |
| 2020 |
$319 million |
| 2021 |
$178 million |
| 2022 |
Approximately $90 million-$100 million |
| 2023 |
Approximately $50 million-$60 million |
Merck reported Zepatier sales in its annual reports as part of pharmaceutical product revenue. The product’s peak year was 2017, when strong demand from U.S. HCV treatment programs and patients with genotype 1 infection supported sales of approximately $1 billion. Sales fell sharply thereafter as the treatment market matured and competing products captured new starts. [2-7]
The commercial pattern was typical of the HCV class: high initial revenue, followed by rapid contraction as diagnosis and treatment of the prevalent patient pool progressed. Unlike chronic therapies, HCV medicines are usually prescribed for a finite course, which limits recurring revenue after the accessible patient population has been treated.
When did elbasvir/grazoprevir lose market exclusivity?
Zepatier’s U.S. regulatory exclusivity began with FDA approval in January 2016. The five-year new chemical entity exclusivity period would have expired in January 2021. Pediatric exclusivity, if granted for the relevant product and listed indications, could extend certain regulatory protections by six months.
Regulatory exclusivity and patent protection are separate. The end of FDA exclusivity did not automatically eliminate patent-based barriers to generic approval or launch. Zepatier’s patent estate included claims directed to HCV protease inhibitors, NS5A inhibitors, combinations and pharmaceutical compositions, with certain rights extending into the early 2030s depending on the specific patent, patent-term adjustment and jurisdiction.
The commercially relevant exclusivity period ended earlier than the outer patent term. By the early 2020s, treatment guidelines and payer behavior had already reduced Zepatier demand.
What patents protect elbasvir/grazoprevir?
The Zepatier patent estate was built around several technical layers:
- Elbasvir composition-of-matter and related NS5A inhibitor claims.
- Grazoprevir composition-of-matter and HCV protease inhibitor claims.
- Fixed-dose combination claims.
- Treatment-method claims for HCV genotype 1 and genotype 4.
- Formulation and pharmaceutical-composition claims.
- Manufacturing and intermediate-related intellectual property.
Public patent records associated with the Zepatier program identify Merck and related Merck entities as principal rights holders. The estate includes U.S. patent families with expiration dates extending into the early 2030s, although the enforceable term can differ by patent because of patent-term adjustment, terminal disclaimers, prosecution history and claim scope.
How strong is the Zepatier patent estate?
The composition-of-matter claims were the strongest layer because they could cover the active ingredient itself or a broad chemical genus. Combination and method-of-use patents were narrower and more vulnerable to design-around strategies.
Patent strength was commercially reduced by four factors:
- Zepatier had no biologic component, so biosimilar barriers were irrelevant.
- A generic applicant could challenge individual patents through an Abbreviated New Drug Application and Paragraph IV certification.
- Competing HCV products did not need to practice Zepatier’s claims.
- The declining value of the product reduced the economic incentive to litigate aggressively.
For investors and generic manufacturers, the key distinction is between the theoretical patent expiry date and the practical launch opportunity. A generic launch would require regulatory approval, resolution of listed patents and a viable market large enough to support manufacturing and distribution. Zepatier’s declining sales reduce the value of a late-entry challenge even if patent protection remains.
What is the Orange Book status of elbasvir/grazoprevir?
Zepatier is an FDA-approved small-molecule drug and is eligible for Orange Book listing. The relevant regulatory pathway for a generic would be an ANDA rather than a biosimilar application.
Orange Book-listed protections may include patents covering:
- The active pharmaceutical ingredients.
- The fixed-dose combination.
- Approved uses.
- Drug product formulation and dosage form.
An ANDA applicant could certify that listed patents are expired, will expire on a specified date, are not infringed or are invalid, or could file a Paragraph IV certification challenging one or more patents. A Paragraph IV notice could trigger patent litigation and a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and litigation outcomes.
The Orange Book is the controlling source for current listed patent numbers, expiration dates and use codes. Merck’s public annual reports establish the product’s commercial and ownership history but are not substitutes for the FDA’s current patent listing. [8]
Which companies are challenging elbasvir/grazoprevir?
No biosimilar company is relevant because elbasvir/grazoprevir is a chemically synthesized small molecule. Potential challengers would be generic drug manufacturers using the ANDA pathway.
The likely competitive group includes large generic manufacturers with experience in antiviral products, such as Teva Pharmaceutical Industries, Viatris, Sandoz, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories and Cipla. Publicly disclosed commercial entry by these companies would depend on FDA filings, Paragraph IV notices, patent litigation and settlement terms.
The absence of a widely visible generic launch does not necessarily indicate a strong patent estate. It can also reflect weak market economics. If annual branded sales have fallen below a level that supports a meaningful generic opportunity, manufacturers may prioritize higher-volume products.
What formulation patents protect Zepatier?
Zepatier is an oral tablet combining elbasvir and grazoprevir. Formulation protection can cover:
- Specific active-ingredient ratios.
- Tablet compositions.
- Excipients and stability characteristics.
- Immediate-release dosage forms.
- Manufacturing processes that preserve chemical stability.
Formulation patents generally provide narrower protection than active-ingredient patents. A generic manufacturer may seek a non-infringing formulation using different excipients or manufacturing conditions while maintaining bioequivalence.
The primary technical barrier for a generic is therefore likely to be the combined effect of active-ingredient, combination and formulation claims rather than a single tablet patent.
What method-of-use patents cover elbasvir/grazoprevir?
Method-of-use protection can cover treatment of HCV genotype 1 or genotype 4, use in patients with cirrhosis, use after prior treatment failure and dosing with or without ribavirin.
Use patents can affect labeling. An ANDA applicant may attempt a skinny-label strategy that omits patented indications while retaining non-patented uses. That approach depends on the scope of the FDA-approved label, physician prescribing behavior and whether the omitted use remains a substantial part of the market.
Zepatier’s market was concentrated in genotype 1 and genotype 4 infections. The availability of broad-label pangenotypic treatments weakened the commercial value of any remaining indication-specific protection.
How does elbasvir/grazoprevir compare with competing HCV drugs?
| Product |
Company |
Key components |
Genotype coverage |
Commercial position |
| Zepatier |
Merck |
Elbasvir/grazoprevir |
Primarily genotypes 1 and 4 |
Declining, mature product |
| Epclusa |
Gilead |
Sofosbuvir/velpatasvir |
Pangenotypic |
Broad guideline positioning |
| Mavyret |
AbbVie |
Glecaprevir/pibrentasvir |
Pangenotypic |
Strong duration and access profile |
| Harvoni |
Gilead |
Ledipasvir/sofosbuvir |
Primarily genotype 1 |
Earlier-generation product |
| Sovaldi-based regimens |
Gilead and partners |
Sofosbuvir combinations |
Depends on partner |
Foundational DAA franchise |
Mavyret gained competitive advantage through pangenotypic coverage, short treatment courses for many patients and aggressive payer contracting. Epclusa also benefited from broad genotype coverage and strong guideline recognition. Zepatier retained clinical utility for selected patients but was less attractive for empiric treatment when genotype and resistance information could be avoided with other regimens.
What FDA regulatory status does Zepatier have?
Zepatier remains an FDA-approved prescription drug for chronic HCV infection within its labeled population. FDA approval does not guarantee continued commercial investment. Merck can maintain the approval while reducing promotion, manufacturing scale and field activity as sales decline.
The product’s regulatory status is therefore stronger than its market status. It remains clinically usable, but treatment guidelines, formularies and procurement programs generally determine whether clinicians select it over pangenotypic alternatives.
What generic entry risks exist for elbasvir/grazoprevir?
Generic entry risk is moderate from a legal perspective and high from a commercial erosion perspective.
Legal entry risk
A generic applicant could pursue:
- Paragraph III certification based on patent expiry.
- Paragraph IV certification challenging validity or infringement.
- A non-infringing formulation.
- A skinny-label product excluding protected indications.
- Entry after a patent settlement or authorized generic arrangement.
The most valuable patents are those covering the active compounds or a broad combination. Narrow method-of-use and formulation claims are more susceptible to workarounds.
Commercial entry risk
Even without a generic launch, Zepatier faces effective substitution from competing branded and generic HCV regimens. In HCV, price pressure can arise through payer negotiation, international procurement and off-patent alternatives before a direct generic version of the branded product reaches the market.
A direct generic launch would likely produce a steep price decline, but the absolute revenue impact to Merck would be limited because Zepatier sales have already contracted substantially from their 2017 peak.
What patent litigation affects elbasvir/grazoprevir?
The principal litigation risk is Hatch-Waxman litigation involving an ANDA applicant and Merck patent holders. The record should be evaluated across three stages:
- Paragraph IV notice and filing of an infringement action.
- FDA approval timing, including any 30-month stay.
- Settlement, judgment or launch at risk.
There is no major publicly established biosimilar litigation pathway for Zepatier. Any material current challenge would be expected to appear in federal court dockets, FDA patent records, Merck disclosures or generic-company filings.
Patent litigation has limited strategic value if the product’s market has already become small. Merck’s likely priority is preserving regulatory continuity and avoiding unnecessary litigation expense rather than extending a declining franchise through broad commercial promotion.
Are there licensing deals involving elbasvir/grazoprevir?
Merck developed Zepatier through its internal HCV research organization and acquired relevant HCV assets through the broader Schering-Plough transaction. The program was associated with Merck’s HCV research and development activities rather than a widely reported late-stage licensing structure comparable to some competing antiviral franchises.
Merck also participated in access and procurement arrangements designed to expand treatment in lower-income markets. Those agreements affected realized price and geographic sales but did not materially change the product’s competitive position in high-income markets.
What is the geographic coverage of the elbasvir/grazoprevir market?
Zepatier received regulatory approvals and commercial distribution in multiple markets, including the United States, Europe and selected international jurisdictions. Demand varied by:
- HCV genotype prevalence.
- Government treatment programs.
- Local reimbursement.
- Generic competition.
- Diagnostic capacity.
- National elimination targets.
The United States was the most important early revenue market. International sales were lower-value because many countries used tender procurement and negotiated discounts. Emerging-market access programs expanded patient reach but contributed less revenue per treatment course.
What manufacturing and intellectual-property barriers remain?
Manufacturing Zepatier requires production of two chemically distinct active ingredients, analytical control of impurities and consistent tablet manufacture. The manufacturing burden is manageable for experienced generic companies but is higher than for a single-active-ingredient product.
Potential barriers include:
- Protected synthetic routes or intermediates.
- Active-ingredient purity specifications.
- Combination-product stability.
- Bioequivalence requirements.
- Regulatory documentation for two active ingredients.
- Low expected sales after launch.
The manufacturing barrier is therefore operational rather than fundamental. The greater obstacle is likely return on investment.
What is the financial outlook for elbasvir/grazoprevir?
Zepatier is a declining, low-growth asset. Its financial trajectory has four phases:
| Phase |
Period |
Market condition |
| Launch |
2016 |
Rapid uptake in genotype 1 and 4 |
| Peak |
2017 |
Approximately $1 billion in sales |
| Erosion |
2018-2020 |
Pangenotypic competition and treated-patient depletion |
| Mature tail |
2021 onward |
Low sales, limited strategic investment |
The asset no longer has the profile of a major growth product. Revenue exposure to Merck is small relative to Keytruda, Gardasil, Prevymis, Bridion and other larger franchises. A generic launch could eliminate most remaining branded sales, but the absolute effect on Merck’s consolidated revenue would be immaterial compared with the product’s peak contribution.
For potential acquirers, the asset has limited standalone value unless bundled with manufacturing rights, geographic registrations or an established HCV distribution platform. For generic companies, the opportunity depends on whether residual demand remains large enough to justify a Paragraph IV challenge and launch investment.
Key Takeaways
- Elbasvir/grazoprevir is Merck’s Zepatier, an oral NS5A inhibitor and NS3/4A protease inhibitor combination.
- FDA approval occurred in January 2016 for chronic HCV genotype 1 and genotype 4.
- Sales peaked at approximately $1 billion in 2017 and declined to a small fraction of that level by the early 2020s.
- Pangenotypic therapies, especially Mavyret and Epclusa, displaced Zepatier in treatment guidelines and payer formularies.
- The product has small-molecule patent protection, so generic ANDA and Paragraph IV strategies are relevant; biosimilar litigation is not.
- Patent rights extend into the early 2030s for certain families, but practical commercial exclusivity weakened much earlier.
- The principal current risk is generic and therapeutic substitution, not loss of a major revenue franchise.
- Zepatier’s remaining value is concentrated in selected genotype 1 and genotype 4 patients, established regulatory approvals and residual international demand.
FAQs About Elbasvir/Grazoprevir
Is elbasvir/grazoprevir still used for hepatitis C treatment?
Yes. Zepatier remains FDA-approved for certain adults with chronic HCV genotype 1 or genotype 4 infection, but pangenotypic therapies are more commonly selected for broad first-line treatment.
Does elbasvir/grazoprevir have a biosimilar risk?
No. Elbasvir/grazoprevir is a chemically synthesized small-molecule drug. The relevant competitive pathway is an ANDA generic, not a biosimilar application.
Did Merck discontinue Zepatier?
Merck’s reported sales declined sharply, but low sales disclosure does not by itself establish withdrawal of the FDA approval. Regulatory availability and active commercial promotion are separate issues.
What is the likely impact of a Zepatier generic launch?
A direct generic launch would likely eliminate most remaining branded sales through price compression and substitution. The impact on Merck’s total revenue would be limited because Zepatier is now a small product.
Which HCV drug is the closest commercial competitor to Zepatier?
Mavyret is the closest major commercial competitor because it offers pangenotypic coverage and a strong treatment-duration profile. Epclusa is another major competitor with broad genotype coverage and extensive guideline use.
References
- U.S. Food and Drug Administration. (2016). FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4.
- Merck & Co., Inc. (2017). 2016 annual report.
- Merck & Co., Inc. (2018). 2017 annual report.
- Merck & Co., Inc. (2019). 2018 annual report.
- Merck & Co., Inc. (2020). 2019 annual report.
- Merck & Co., Inc. (2021). 2020 annual report.
- Merck & Co., Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- American Association for the Study of Liver Diseases and Infectious Diseases Society of America. (2023). HCV guidance: Recommendations for testing, managing, and treating hepatitis C.
